Charlotte's Web Holdings Inc (CWBHF)

[DarthYoda]

Here is some reading including an update from Alan Brochstein...

"Bottoming Out but Not Yet a Rally":
August 21, 2022
https://www.newcannabisventures.com/bottoming-out-but-not-yet-a-rally/

"House Passes Bill to Expand Cannabis and CBD Research":
August 15, 2022

In late July, the U.S. House of Representatives passed H.R. 8454, the Medical Marijuana and Cannabidiol Research Expansion Act (Research Expansion Act). A similar version of the bill, S. 253, passed the Senate earlier this year. The bill is expected to head to President Biden after the bills are reconciled.

Among other things, the bill would ease limitations on medical research on cannabis and cannabidiol (CBD). Specifically, the bill would:

-Direct the U.S. Drug Enforcement Administration (DEA) to register practitioners to conduct cannabis and CBD research and manufacturers to supply cannabis for research purposes. The bill expressly allows the DEA to register manufacturers and distributors of cannabis or CBD for the purpose of commercial production of a drug approved by the U.S. Food and Drug Administration (FDA).
-Require the DEA to assess whether there is an adequate and uninterrupted supply of cannabis for research purposes.
-Permit registered entities to manufacture, distribute, dispense, or possess marijuana or CBD for the purposes of medical research.
-Clarify that physicians do not violate the Controlled Substances Act (CSA) when they discuss the potential harms and benefits of cannabis and CBD with patients.
-Direct the U.S. Department of Health & Human Services (DHHS) to coordinate with the National Institutes of Health (NIH) and other agencies to report on the “therapeutic potential” of cannabis for conditions such as epilepsy, the impact of cannabis on adolescent brain development, and cannabis’ effects on the ability to operate a motor vehicle.

Congress continues to debate various measures to legalize and deschedule cannabis, most notably the recently introduced Cannabis Administration and Opportunity Act. The Research Expansion Act presents an important step in the process of federal regulation of the nation’s cannabis industry. This will be the first cannabis-related bill to reach the Oval Office. While the president has not expressed support for full legalization, he has signaled his support for medical cannabis research.

https://www.cannabislegalhighlights.com/2022/08/house-passes-bill-to-expand-cannabis-and-cbd-research/

"How The 2023 Farm Bill May Reshape The Hemp Industry":
Aug 3, 2022,
https://www.forbes.com/sites/dariosabaghi/2022/08/03/how-the-2023-farm-bill-may-reshape-the-hemp-industry/?sh=332c97c67a67


"D.C. Lawmakers Talk Hemp Ahead of 2023 Farm Bill":
August 1, 2022
https://www.greenmarketreport.com/d-c-lawmakers-talk-hemp-ahead-of-2023-farm-bill/

"Plaskett Chairs Agriculture Subcommittee Hearing on USDA Hemp Production Program":
July 29, 2022

Congresswoman Tracy Plaskett, a member of the House Ways and Means, Budget and Agriculture Committees, released the following statement after chairing a Biotechnology, Horticulture and Research (BHR) hearing entitled “An Examination of the USDA Hemp Production Program.”

“The Subcommittee on Biotechnology, Horticulture and Research has authority over the hemp industry; as such, today the subcommittee heard from a panel of experts, including producers, researchers, tribal members and State Agriculture directors and commissioners who provided a review of the USDA Hemp Production Program authorized in the 2018 Farm Bill (P.L. 115-334) as well as an update on the current state of domestic hemp production.

“The witnesses shared information about the market complexities that emerged following the 2018 Farm Bill as well as steps the House Agriculture Committee can take to ensure states, territories and tribes are providing the necessary support to producers. Our witnesses shared that prior to 2018, the federal prohibition and controlled substance classification of hemp presented the largest barrier to industrial hemp production. Following the 2018 Farm Bill, new issues have emerged, including a lack of uniform state regulations and testing processes as well as clear federal enforcement standards, and other barriers.

“In addition, the subcommittee received requests for greater market certainty and stability for farmers, producers and consumers of the hemp industry. We also heard about industry successes, which include creating space for market diversification as well as addressing gaps and limits in the supply chain, including processing and manufacturing, increasing production capacity, and strengthening the links between the supply chain.

“In my district, the U.S. Virgin Islands, farmers are keenly interested in the economic growth and expansion opportunities presented by the hemp industry. As we continue conversations leading up to the 2023 Farm Bill, we must ensure we include the voices of socially disadvantaged farmers, increase their involvement in these important discussions and generate equity across the industry.

“I look forward to continuing conversations about the hemp industry as well as engaging with the Virgin Islands community on the important takeaways from this subcommittee hearing and encourage agriculture stakeholders to visit https://agriculture.house.gov/forms/form/?ID=9 and provide the House Agriculture Committee with direct input on their experiences with Farm Bill programs.”

https://stthomassource.com/content/2022/07/29/plaskett-chairs-agriculture-subcommittee-hearing-on-usda-hemp-production-program/

"An Examination of the USDA Hemp Production Program":

"Why More And More Athletes Are Turning To CBD Topicals":
Aug 18, 2022
https://www.sportingfree.com/athletes/why-more-and-more-athletes-are-turning-to-cbd-topicals/